Combangio
The business, the turning points, and the decisions behind them.
Some sections are still being researched1 / 4
Sections to complete：02
01 / WHAT IT BUILT
What the company did
Combangio was a private, clinical-stage biotech developing regenerative biotherapies for severe ocular surface diseases. Its lead candidate CMB-012 was a novel mesenchymal stem cell (MSC) secretome therapy - a topical ocular solution of protease inhibitors, growth factors, and neurotrophic factors secreted by MSCs - in clinical development for persistent corneal epithelial defect (PCED), a rare non-healing corneal wound that received FDA Orphan Designation.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Acquired by Kala Pharmaceuticals
On November 15, 2021, Kala Pharmaceuticals acquired Combangio; the therapy was renamed KPI-012. Former Combangio equityholders received an upfront payment of cash and Kala common stock worth approximately $21 million in aggregate; Wilson Sonsini represented Combangio in the transaction.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Raised approximately $15 million in total.
- 02
On November 15, 2021 it was acquired by Kala Pharmaceuticals (later renamed KALA BIO); shareholders received about $21 million in cash and stock; the lead candidate was renamed KPI-012 and later won FDA orphan-drug and fast-track designations.
- 03
No audited loss figure was publicly disclosed.